- Document Number:
20250057182
- Appl. No:
18/935724
- Application Filed:
November 04, 2024
- Abstract:
Therefore, disclosed herein is a composition comprising dietary early glycation products (EGPs) with less than 1 wt % advanced glycation end products (AGEs). Also disclosed is a method for treating or preventing diabetes in a subject, such as type 1 diabetes, type 2 diabetes, or gestational diabetes, that involves administering to a subject in need thereof a composition disclosed herein.
- Claim:
1. A method for treating or preventing an autoimmune disease in a subject, comprising administering to the subject a composition comprising a glycated α-lactalbumin, a glycated β-lactoglobulin, or a combination thereof.
- Claim:
2. The method of claim 1, wherein the autoimmune disease comprises type 1 diabetes or gestational diabetes.
- Claim:
3. The method of claim 1, wherein the method delays the onset of type 1 diabetes in the subject.
- Claim:
4. The method of claim 1, wherein the method reduces the incidence of type 1 diabetes in the subject.
- Claim:
5. The method of claim 1, wherein the autoimmune disease comprises autoimmune prostatitis.
- Claim:
6. The method of claim 1, wherein the glycated α-lactalbumin has 1 to 12 glucose moieties, and the glycated β-lactoglobulin has 1 to 16 glucose moieties.
- Claim:
7. The method of claim 1, wherein the glycated β-lactoglobulin comprises glycated β-lactoglobulin A, glycated β-lactoglobulin B, or a combination thereof.
- Claim:
8. The method of claim 1, wherein the composition comprises at least 95 wt % glycated α-lactalbumin and glycated β-lactoglobulin.
- Claim:
9. The method of claim 1, wherein the composition comprises glycated α-lactalbumin, wherein at least 74% of the glycated α-lactalbumin has 6 glucose moieties.
- Claim:
10. The method of claim 1, wherein the composition comprises glycated β-lactoglobulin, wherein at least 54% of the glycated β-lactoglobulin has 10 glucose moieties.
- Claim:
11. The method of claim 1, wherein the composition is produced by a process comprising dissolving a protein isolate capable of forming glycation products and glucose in water, freeze-drying the solution to produce a powder, and incubating the powder in heated dry air.
- Claim:
12. The method of claim 11, wherein the protein isolate comprises a whey protein isolate (WPI).
- Claim:
13. The method of claim 12, wherein the ratio of WPI to glucose is in a molar ratio of free amino groups and reducing ends at 1:2.
- Claim:
14. The method of claim 1, wherein the composition further comprises a nutraceutically acceptable excipient.
- Claim:
15. The method of claim 1, wherein the composition is a solid unit dose form.
- Claim:
16. The method of claim 15, wherein the solid unit dose form comprises an enteric coating.
- Claim:
17. The method of claim 15, wherein the solid unit dose form comprises tablets, beads, or granules.
- Claim:
18. The method of claim 1, wherein the autoimmune disease comprises type 1 diabetes, and the subject is administered a composition comprising a mixture of the glycated α-lactalbumin and the glycated β-lactoglobulin, and wherein the glycated α-lactalbumin has 1 to 12 glucose moieties, and the glycated β-lactoglobulin has 1 to 16 glucose moieties.
- Claim:
19. The method of claim 18, wherein the composition is produced by a process comprising dissolving a protein isolate capable of forming glycation products and glucose in water, freeze-drying the solution to produce a powder, and incubating the powder in heated dry air.
- Claim:
20. The method of claim 19, wherein the protein isolate comprises a whey protein isolate (WPI).
- Current International Class:
23; 23
- Accession Number:
edspap.20250057182
Processing Request
No Comments.